MEK/PD-L1 Inhibition Fails in Third-Line Colon Cancer

(MedPage Today) — Phase III IMblaze370, designed to overcome immune-resistance of tumors, a ‘great disappointment,’ researchers say

Source link

Related posts

VIDEO: Digital marketing offers a ‘clear’ return on investment for physicians


Risk model for ileocecal resection includes imaging features, age


FDA OK's Another PD-1 Inhibitor for HCC


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy